

Guillaume Robert

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5434759/publications.pdf>

Version: 2024-02-01

67
papers

3,307
citations

172457

29
h-index

144013

57
g-index

69
all docs

69
docs citations

69
times ranked

8505
citing authors

#	ARTICLE	IF	CITATIONS
1	Reprogramming monocyte-derived macrophages through caspase inhibition. <i>Oncolmmunology</i> , 2022, 11, 2015859.	4.6	3
2	Dual Covalent Inhibition of PKM and IMPDH Targets Metabolism in Cutaneous Metastatic Melanoma. <i>Cancer Research</i> , 2021, 81, 3806-3821.	0.9	9
3	Ultrasound-assisted one-pot three-component synthesis of new isoxazolines bearing sulfonamides and their evaluation against hematological malignancies. <i>Ultrasonics Sonochemistry</i> , 2021, 78, 105748.	8.2	12
4	Acadesine Circumvents Azacitidine Resistance in Myelodysplastic Syndrome and Acute Myeloid Leukemia. <i>International Journal of Molecular Sciences</i> , 2020, 21, 164.	4.1	8
5	Clonal selection in therapy-related myelodysplastic syndromes and acute myeloid leukemia under azacitidine treatment. <i>European Journal of Haematology</i> , 2020, 104, 488-498.	2.2	6
6	Chaperone-Mediated Autophagy and Its Emerging Role in Hematological Malignancies. <i>Cells</i> , 2019, 8, 1260.	4.1	21
7	Caspase 1/11 Deficiency or Pharmacological Inhibition Mitigates Psoriasis-Like Phenotype in Mice. <i>Journal of Investigative Dermatology</i> , 2019, 139, 1306-1317.	0.7	16
8	Azacitidine resistance caused by LAMP2 deficiency: a therapeutic window for the use of autophagy inhibitors in MDS/AML patients?. <i>Autophagy</i> , 2019, 15, 927-929.	9.1	12
9	Modulation of the ATM/autophagy pathway by a G-quadruplex ligand tips the balance between senescence and apoptosis in cancer cells. <i>Nucleic Acids Research</i> , 2019, 47, 2739-2756.	14.5	50
10	The oncogenic tyrosine kinase Lyn impairs the pro-apoptotic function of Bim. <i>Oncogene</i> , 2018, 37, 2122-2136.	5.9	8
11	IL-34 and CSF-1 display an equivalent macrophage differentiation ability but a different polarization potential. <i>Scientific Reports</i> , 2018, 8, 256.	3.3	149
12	Modular synthesis of new C-aryl-nucleosides and their anti-CML activity. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2018, 28, 1931-1936.	2.2	8
13	Implication and Regulation of AMPK during Physiological and Pathological Myeloid Differentiation. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2991.	4.1	26
14	ATP-competitive Plk1 inhibitors induce caspase 3-mediated Plk1 cleavage and activation in hematopoietic cell lines. <i>Oncotarget</i> , 2018, 9, 10920-10933.	1.8	2
15	In Vitro and in Vivo Evaluation of Fully Substituted		

#	ARTICLE	IF	CITATIONS
19	Sirtuin 7: a new marker of aggressiveness in prostate cancer. <i>Oncotarget</i> , 2017, 8, 77309-77316.	1.8	24
20	BCL-B (BCL2L10) is overexpressed in patients suffering from multiple myeloma (MM) and drives an MM-like disease in transgenic mice. <i>Journal of Experimental Medicine</i> , 2016, 213, 1705-1722.	8.5	24
21	Differentiation inducing factor 3 mediates its anti-leukemic effect through ROS-dependent DRP1-mediated mitochondrial fission and induction of caspase-independent cell death. <i>Oncotarget</i> , 2016, 7, 26120-26136.	1.8	14
22	Autophagy and blood diseases. <i>Hematologie</i> , 2015, 21, 107-116.	0.0	0
23	The PRKAA1/AMPK $\hat{+}$ 1 pathway triggers autophagy during CSF1-induced human monocyte differentiation and is a potential target in CMML. <i>Autophagy</i> , 2015, 11, 1114-1129.	9.1	86
24	FeCl ₃ -promoted and ultrasound-assisted synthesis of resveratrol O-derived glycoside analogs. <i>Ultrasonics Sonochemistry</i> , 2015, 22, 15-21.	8.2	18
25	Involvement of autophagy in cellular development and differentiation. <i>Hematologie</i> , 2015, 21, 212-220.	0.0	0
26	Implication of the Anti-Apoptotic Protein Bcl-B (BCL2L10) in the Pathogenesis of Multiple Myeloma. <i>Blood</i> , 2015, 126, 2958-2958.	1.4	0
27	Decreased Expression of Anti-DNMT1 Tumor-Suppressor microRNAs in Azacitidine (AZA)-Resistant Cells Independently Predicts Survival in Patients Treated with AZA for Higher Risk Myelodysplastic Syndrome (HRMDS) and Oligoblastic Acute Myeloid Leukemia (AML). <i>Blood</i> , 2015, 126, 2840-2840.	1.4	0
28	A new posttranslational regulation of REDD1/DDIT4 through cleavage by caspase 3 modifies its cellular function. <i>Cell Death and Disease</i> , 2014, 5, e1349-e1349.	6.3	5
29	Limbic versus cognitive target for deep brain stimulation in treatment-resistant depression: Accumbens more promising than caudate. <i>European Neuropsychopharmacology</i> , 2014, 24, 1229-1239.	0.7	56
30	Hearing Loss During Osteosarcoma Chemotherapy. <i>Journal of Pediatric Hematology/Oncology</i> , 2014, 36, e100-e102.	0.6	6
31	Successful re-treatment of a relapsed V600E mutated HCL patient with low-dose vemurafenib. <i>Oncoscience</i> , 2014, 2, 44-49.	2.2	18
32	Phenotypic and genotypic characterization of azacitidine-sensitive and resistant SKM1 myeloid cell lines. <i>Oncotarget</i> , 2014, 5, 4384-4391.	1.8	17
33	The small heat shock protein B8 (HSPB8) confers resistance to bortezomib by promoting autophagic removal of misfolded proteins in multiple myeloma cells. <i>Oncotarget</i> , 2014, 5, 6252-6266.	1.8	43
34	The P2Y6-AMPK Pathway Triggers Autophagy during CSF-1-Induced Human Monocyte Differentiation and Is a Potential Target in CMML. <i>Blood</i> , 2014, 124, 4347-4347.	1.4	0
35	BCL2L10 Quantification Is a Predictive Factor of Response to Azacitidine in Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML). <i>Blood</i> , 2014, 124, 3261-3261.	1.4	0
36	Ponatinib circumvents all types of imatinib resistance in chronic myelogenous leukemia cell lines. <i>Cell Cycle</i> , 2013, 12, 1645-1646.	2.6	7

#	ARTICLE	IF	CITATIONS
37	Low-dose vemurafenib induces complete remission in a case of hairy-cell leukemia with a V600E mutation. <i>Haematologica</i> , 2013, 98, e20-e22.	3.5	53
38	How Recent Advances in High-risk Myelodysplastic Syndrome Physiopathology May Impact Future Treatments. <i>Current Pharmaceutical Design</i> , 2013, 19, 5362-5373.	1.9	3
39	Evaluation Of Acaesine, a Drug Stimulating Cell Autophagy, In Azacitidine(AZA)-Resistant Myelodysplastic Syndromes (MDS). <i>Blood</i> , 2013, 122, 1568-1568.	1.4	0
40	Imatinib triggers mesenchymal-like conversion of CML cells associated with increased aggressiveness. <i>Journal of Molecular Cell Biology</i> , 2012, 4, 207-220.	3.3	32
41	The anti-apoptotic Bcl-B protein inhibits BECN1-dependent autophagic cell death. <i>Autophagy</i> , 2012, 8, 637-649.	9.1	45
42	Autophagy is required for CSF-1 α -induced macrophagic differentiation and acquisition of phagocytic functions. <i>Blood</i> , 2012, 119, 4527-4531.	1.4	123
43	Ultrasound-assisted one-pot synthesis of anti-CML nucleosides featuring 1,2,3-triazole nucleobase under iron-copper catalysis. <i>Ultrasonics Sonochemistry</i> , 2012, 19, 1132-1138.	8.2	56
44	BCL2L10 is a predictive factor for resistance to Azacitidine in MDS and AML patients. <i>Oncotarget</i> , 2012, 3, 490-501.	1.8	75
45	All tyrosine kinase inhibitor-resistant chronic myelogenous cells are highly sensitive to Ponatinib. <i>Oncotarget</i> , 2012, 3, 1557-1565.	1.8	30
46	The caspase 6 derived N-terminal fragment of DJ-1 promotes apoptosis via increased ROS production. <i>Cell Death and Differentiation</i> , 2012, 19, 1769-1778.	11.2	19
47	BCL2L10 (Bcl-B) Is Associated with Resistance to Azacitidine (AZA) in MDS and AML, and Is a Possible Therapeutic Target in AZA Resistant Patients. <i>Blood</i> , 2012, 120, 701-701.	1.4	2
48	Simalikalactone E (SkE), a new weapon in the armamentarium of drugs targeting cancers that exhibit constitutive activation of the ERK pathway. <i>Oncotarget</i> , 2012, 3, 1688-1699.	1.8	11
49	Metformin, Independent of AMPK, Induces mTOR Inhibition and Cell-Cycle Arrest through REDD1. <i>Cancer Research</i> , 2011, 71, 4366-4372.	0.9	545
50	Metformin inhibits melanoma development through autophagy and apoptosis mechanisms. <i>Cell Death and Disease</i> , 2011, 2, e199-e199.	6.3	250
51	The p53/p21 ^{Cip1} /Waf1 pathway mediates the effects of SPARC on melanoma cell cycle progression. <i>Pigment Cell and Melanoma Research</i> , 2011, 24, 219-232.	3.3	36
52	A New Hydroxylated Nonaprenylhydroquinone from the Mediterranean Marine Sponge <i>Sarcotragus spinosulus</i> . <i>Marine Drugs</i> , 2011, 9, 1210-1219.	4.6	20
53	Azacitidine-resistant SKM1 myeloid cells are defective for AZA-induced mitochondrial apoptosis and autophagy. <i>Cell Cycle</i> , 2011, 10, 2339-2343.	2.6	37
54	Mechanism of action of the multikinase inhibitor Foretinib. <i>Cell Cycle</i> , 2011, 10, 4138-4148.	2.6	28

#	ARTICLE	IF	CITATIONS
55	Mechanisms of AXL overexpression and function in Imatinib-resistant chronic myeloid leukemia cells. <i>Oncotarget</i> , 2011, 2, 874-885.	1.8	99
56	Cathepsin B release after imatinib-mediated lysosomal membrane permeabilization triggers BCR α -ABL cleavage and elimination of chronic myelogenous leukemia cells. <i>Leukemia</i> , 2010, 24, 115-124.	7.2	43
57	Resveratrol Promotes Autophagic Cell Death in Chronic Myelogenous Leukemia Cells via JNK-Mediated p62/SQSTM1 Expression and AMPK Activation. <i>Cancer Research</i> , 2010, 70, 1042-1052.	0.9	335
58	Persistent Activation of the Fyn/ERK Kinase Signaling Axis Mediates Imatinib Resistance in Chronic Myelogenous Leukemia Cells through Upregulation of Intracellular SPARC. <i>Cancer Research</i> , 2010, 70, 9659-9670.	0.9	56
59	Targeting autophagy to fight hematopoietic malignancies. <i>Cell Cycle</i> , 2010, 9, 3470-3478.	2.6	70
60	Induction of Autophagic Cell Death Circumvents Azacitidine-Resistance In Myelodysplastic Syndrome-Derived Cell Lines. <i>Blood</i> , 2010, 116, 1817-1817.	1.4	1
61	Spleen Tyrosine Kinase Functions as a Tumor Suppressor in Melanoma Cells by Inducing Senescence-like Growth Arrest. <i>Cancer Research</i> , 2009, 69, 2748-2756.	0.9	69
62	Autophagy is an important event for megakaryocytic differentiation of the chronic myelogenous leukemia K562 cell line. <i>Autophagy</i> , 2009, 5, 1092-1098.	9.1	92
63	Dual Role of Sp3 Transcription Factor as an Inducer of Apoptosis and a Marker of Tumour Aggressiveness. <i>PLoS ONE</i> , 2009, 4, e4478.	2.5	29
64	Acadesine Kills Chronic Myelogenous Leukemia (CML) Cells through PKC-Dependent Induction of Autophagic Cell Death. <i>PLoS ONE</i> , 2009, 4, e7889.	2.5	79
65	Tumor-Derived Fibronectin Is Involved in Melanoma Cell Invasion and Regulated by V600E B-Raf Signaling Pathway. <i>Journal of Investigative Dermatology</i> , 2007, 127, 400-410.	0.7	51
66	SPARC Represses E-Cadherin and Induces Mesenchymal Transition during Melanoma Development. <i>Cancer Research</i> , 2006, 66, 7516-7523.	0.9	145
67	HGF induces fibronectin matrix synthesis in melanoma cells through MAP kinase-dependent signaling pathway and induction of Egr-1. <i>Oncogene</i> , 2005, 24, 1423-1433.	5.9	71